Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

Part of paid clinical trials in Bethesda, Maryland.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT00217503
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
  • filgrastim — BIOLOGICAL
  • pegfilgrastim — BIOLOGICAL
  • bortezomib — DRUG
  • cyclophosphamide — DRUG
  • doxorubicin hydrochloride — DRUG
  • etoposide — DRUG
  • ganciclovir — DRUG
  • valganciclovir — DRUG
  • zidovudine — DRUG

Study Details

RATIONALE: Herpesvirus is found in the cancer cells of patients with primary effusion lymphoma. Antiviral drugs, such as zidovudine and valganciclovir, may be able to act against the herpesvirus in the cancer cells to help kill the cancer cells. Bortezomib may help the antiviral drugs kill the cancer cells. Draining the effusion removes fluid that has built up. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab may also stop the growth of cancer cells by blocking blood flow to the cancer. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with antiviral therapy followed by effusion drainage, bevacizumab, and combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with antiviral therapy followed by effusion drainage, bevacizumab, and combination chemotherapy works in treating patients with primary effusion lymphoma.

Key Dates

First listed
Sep 22, 2005
Start date
Jul 31, 2005
Status verified
Apr 2007
Completion
Jun 30, 2007

Study Design

Enrollment
15 participants (estimated)
Primary purpose
TREATMENT

Primary Outcome Measure

Response to therapy as measured by overall, disease-free, and progression-free survival each month

Locations (1)

FacilityCityStateZIPSite coordinators
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral OfficeBethesdaMaryland20892-1182-

Find similar trials in Bethesda, MD

By research site
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office· Bethesda, MD

Related Studies